Open main menu

Psychiatrienet β

Fluvoxamine-mianserine

Revision as of 11:21, 17 November 2009 by Mariska (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine
Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine

Switch medication from fluvoxamine to mianserine.[1] [2]

Nietinrijdenbord.png Stop fluvoxamine
  • Before day 1: gradually reduce dosage of fluvoxamine to a maximum of 50 mg/ day, when this dosage is > 50 mg/day.
  • Day 1: reduce fluvoxamine to a dosage of 25 mg/day.
Eenrichtingbord.png Start mianserine
  • Day 1: simultaneously start administration of mianserine in a low dosage of 30 mg/day for one week.
  • Day 8: stop administration of fluvoxamine and continue administration of mianserine only. If necessary increase dosage of mianserine to normal (60 mg/day).


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.